Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study

Critical Care Medicine

Volumn 31, Issue 6, 2003, Pages 1839-1847

  De Kleijn, Ester D ^a   De Groot, Ronald ^a   Hack, C Erik ^b   Mulder, Paul G H ^c   Engl, Werner ^d   Moritz, Berta ^d   Joosten, Koen F M ^a   Hazelzet, Jan A ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d BAXTER BIOSCIENCE   (Austria)

Author keywords

Activated protein C; Disseminated intravascular coagulation; Meningococcal sepsis; Protein C; Randomized, placebo controlled trial; Septic shock

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; ANTIBIOTIC AGENT; D DIMER; DOBUTAMINE; GLYCERYL TRINITRATE; HUMAN VAPOR HEATED; INOTROPIC AGENT; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; NORADRENALIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; PROTEIN C; THROMBIN; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE AGENT; VASODILATOR AGENT;

ADOLESCENT; ARTICLE; BLOOD CLOTTING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FULMINATING PURPURA; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFANT; MALE; MENINGOCOCCEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK;

ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INFANT; INTERLEUKIN-6; MALE; MENINGOCOCCAL INFECTIONS; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROTEIN C; PURPURA, SCHOENLEIN-HENOCH; REGRESSION ANALYSIS; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 0038128677     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000072121.61120.D8     Document Type: Article

References (37)

1. Powars DR, Rogers ZR, Patch MJ, et al: Purpura fulminans in meningococcemia: Association with acquired deficiencies of proteins C and S. N Engl J Med 1987; 317:571-572
2. Leclerc F, Hazelzet J, Jude B, et al: Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases. Intensive Care Med 1992; 18:202-205
3. Esmon CT: The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chern 1989; 264:4743-4746
4. Katsuura Y, Aoki K, Tanabe H, et al: Characteristic effects of activated human protein C on tissue thromboplastin-induced disseminated intravascular coagulation in rabbits. Thromb Res 1994; 76:353-362
5. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270:14477-14484
6. Taylor FB Jr, Chang A, Esmon CT, et al: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79:918-925
7. Taylor F, Chang A, Ferrell G, et al: C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991; 78:357-363
8. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, et al: The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95:1680-1686
9. Blanco A, Guisasola JA, Solis P, et al: Fibronectin in meningococcal sepsis: Correlation with antithrombin III and protein C. Acta Paediatr Scand 1990; 79:73-76
10. Brandtzaeg P, Sandset PM, Joo GB, et al: The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989; 55:459-470
11. Fijnvandraat K, Peters M, Derkx B, et al: Endotoxin induced coagulation activation and protein C reduction in meningococcal septic shock. Prog Clin Biol Res 1994; 388:247-254
12. Fourrier F, Lestavel P, Chopin C, et al: Meningococcemia and purpura fulminans in adults: Acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990; 16:121-124
13. Hesselvik JF, Malm J, Dahlback B, et al: Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991; 65:126-129
14. Hazelzet JA, Risseeuw-Appel IM, Komelisse RF, et al: Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost 1996; 76:932-938
15. Roback MG, Stack AM, Thompson C, et al: Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits [see comments]. Shock 1998; 9:138-142
16. Ettingshausen CE, Veldmann A, Beeg T, et al: Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 1999; 25:537-541
17. Gerson WT, Dickerman JD, Bovill EG, et al: Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate. Pediatrics 1993; 91:418-422
18. Kreuz W, Veldman A, Escuriola-Ettingshausen C, et al: Protein-C concentrate for meningococcal purpura fulminans. Lancet 1998; 3351:986-987
19. Rintala E, Kauppila M, Seppala OP, et al: Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 2000; 28:2373-2378
20. Rivard GE, David M, Farrell C, et al: Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995; 126:646-652
21. Smith OP, White B, Vaughan D, et al: Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans [see comments]. Lancet 1997; 350:1590-1593
22. White B, Livingstone W, Murphy C, et al: An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96:3719-3724
23. Conard J, Bauer KA, Gruber A, et al: Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood 1993; 82:1159-1164
24. Faust SN, Levin M, Harrison OB, et al: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408-416
25. Vincent JL, De Mendonca A, Cantraine F, et al: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Crit Care Med 1998; 26:1793-1800
26. Pollack MM, Ruttimann UE, Getson PR: Pediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16:1110-1116
27. Kornelisse RF, Hazelzet JA, Hop WC, et al: Meningococcal septic shock in children: Clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis 1997; 25:640-646
28. Gruber A, Griffin JH: Direct detection of activated protein C in blood from human subjects. Blood 1992; 79:2340-2348
29. Hazelzet JA, de Kleijn ED, de Groot R: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:1776-1777
30. Kornelisse RF, Hazelzet JA, Savelkoul HFJ, et al: The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996; 173:1148-1156
31. Mesters RM, Helterbrand J, Utterback BG, et al: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000; 28:2209-2216
32. Fijnvandraat K, Derkx B, Peters M, et al: Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality. Thromb Haemost 1995; 73:15-20
33. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
34. de Boer JP, Abbink JJ, Brouwer MC, et al: PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines: Evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost 1991; 65:181-185
35. Boermeester M, van Leeuwen P, Coyle S, et al: IL-1 receptor antagonist (IL-1ra) attenuates activation of the complement, coagulation and fibrinolytic systemsin patietns with sepsis. Surg Forum 1994; 45:23-25
36. Levi M, de Boer JP, Roem D, et al: Plasminogen activation in vivo upon intravenous infusion of DDAVP: Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992; 67:111-116
37. Lee ML, Poon WY, Kingdon HS: A two-phase linear regression model for biologic half-life data. J Lab Clin Med 1990; 115:745-748